If you’ve heard the buzz about oral probiotics, lozenges or melts that deliver beneficial bacteria to your mouth, you’re not ...
As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...
Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...
The first sickle cell disease patient has been enrolled in a Phase 1b trial testing iadademstat, Oryzon Genomics' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback